Envoy Medical, Inc. (COCH): Nasdaq/NYSE listing notice — Envoy Medical regains compliance with Nasdaq listing requirement after MVLS deficiency

Envoy Medical, Inc.

Received Nasdaq letter confirming compliance with Listing Rule 5550(b)(2) after MVLS fell below $35M.
Discretionary panel monitor imposed for one year from February 12, 2026.
Company implemented strategic financing initiatives to strengthen balance sheet and regain compliance.
Original non-compliance notice received February 25, 2025; now resolved.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Envoy Medical, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(2), 5815(d)(4)(B)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: stockholders equity
Rules: 5550(b)(2), 5815(d)(4)(B)

Exact text from the filing

February 23, 2026, Envoy Medical, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Hearings office confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) in compliance with the Nasdaq Hearing Panel’s letter dated October 23, 2025. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a discretionary panel monitor for a period of one year from February 12, 2026.

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Envoy Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-021116

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.